IDENIX PHARM
Norcod AS engages in the farming, production, operation, distribution, marketing, and sale of farmed cod products in Norway and internationally. The company was incorporated in 2018 and is headquartered in Trondheim, Norway.
IDENIX PHARM (NO9) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: -0.528x
Based on the latest financial reports, IDENIX PHARM (NO9) has a cash flow conversion efficiency ratio of -0.528x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-73.86 Million) by net assets (€139.91 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
IDENIX PHARM - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how IDENIX PHARM's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
IDENIX PHARM Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of IDENIX PHARM ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Sino Horizon Holdings Ltd
TW:2923
|
-0.028x |
|
SRG Mining Inc
PINK:SRGMF
|
-0.243x |
|
Wafangdian Bearing Co Ltd
SHE:200706
|
0.884x |
|
Proteomics International Laboratories Ltd
AU:PIQ
|
-0.416x |
|
Alves Kablo San As
IS:ALVES
|
-0.092x |
|
Southern Acids (M) Bhd
KLSE:5134
|
0.052x |
|
Astro Malaysia Holdings Bhd
KLSE:6399
|
0.127x |
|
Korea Ind
KO:002140
|
0.102x |
Annual Cash Flow Conversion Efficiency for IDENIX PHARM (2019–2024)
The table below shows the annual cash flow conversion efficiency of IDENIX PHARM from 2019 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-09-30 | €156.09 Million | €-186.11 Million | -1.192x | -16.02% |
| 2023-09-30 | €224.81 Million | €-231.02 Million | -1.028x | +10.02% |
| 2022-09-30 | €176.68 Million | €-201.78 Million | -1.142x | -314.49% |
| 2021-09-30 | €309.24 Million | €-85.20 Million | -0.276x | +24.61% |
| 2020-09-30 | €388.10 Million | €-141.85 Million | -0.365x | +63.83% |
| 2019-09-30 | €29.97 Million | €-30.28 Million | -1.010x | -- |